Literature DB >> 27500319

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine.

Tinen L Iles1, Brian Howard2, Stephen Howard3, Stephen Quallich2, Christopher Rolfes2, Eric Richardson4, Hanna R Iaizzo5, Paul A Iaizzo6.   

Abstract

To date, many pharmacological agents used to treat or prevent arrhythmias in open-heart cases create undesired systemic side effects. For example, antiarrhythmic drugs administered intravenously can produce drops in systemic pressure in the already compromised cardiac patient. While performing open-heart procedures, surgeons will often either create a small port or form a pericardial cradle to create suitable fields for operation. This access yields opportunities for target pharmacological delivery (antiarrhythmic or ischemic preconditioning agents) directly to the myocardial tissue without undesired side effects. We have developed a swine model for testing pharmacological agents for target delivery within the pericardial fluid. While fully anesthetized, each animal was instrumented with a Swan-Ganz catheter as well as left and right ventricle pressure catheters, and pacing leads were placed in the right atrial appendage and the right ventricle. A medial sternotomy was then performed and a pericardial access cradle was created; a plunge pacing lead was placed in the left atrial appendage and a bipolar pacing lead was placed in the left ventricle. Utilizing a programmer and a cardiac mapping system, the refractory period of the atrioventricular node (AVN), atria and ventricles was determined. In addition, atrial fibrillation (AF) induction was produced utilizing a Grass stimulator and time in AF was observed. These measurements were performed prior to treatment, as well as 30 min and 60 min after pericardial treatment. Additional time points were added for selected studies. The heart was then cardiopleged and reanimated in a four chamber working mode. Pressure measurements and function were recorded for 1 hr after reanimation. This treatment strategy model allowed us to observe the effects of pharmacological agents that may decrease the incidence of cardiac arrhythmias and/or ischemic damage, during and after open-heart surgery.

Entities:  

Mesh:

Year:  2016        PMID: 27500319      PMCID: PMC4993382          DOI: 10.3791/52600

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  11 in total

1.  Distribution of amiodarone in heart tissues following intrapericardial administration.

Authors:  J T Darsinos; J N Karli; E C Samouilidou; B Krumbholz; A C Pistevos; G M Levis
Journal:  Int J Clin Pharmacol Ther       Date:  1999-06       Impact factor: 1.366

2.  Isolated four-chamber working swine heart model.

Authors:  E Chinchoy; C L Soule; A J Houlton; W J Gallagher; M A Hjelle; T G Laske; J Morissette; P A Iaizzo
Journal:  Ann Thorac Surg       Date:  2000-11       Impact factor: 4.330

3.  Intrapericardial delivery enhances cardiac effects of sotalol and atenolol.

Authors:  Thomas J van Brakel; J J Rob Hermans; Ben J Janssen; Helma van Essen; Nicole Botterhuis; Jos F M Smits; Jos G Maessen
Journal:  J Cardiovasc Pharmacol       Date:  2004-07       Impact factor: 3.105

4.  Cardiac responses to the intrapericardial delivery of metoprolol: targeted delivery compared to intravenous administration.

Authors:  Eric S Richardson; Christopher Rolfes; Oh Sang Woo; William F Elmquist; David G Benditt; Paul A Iaizzo
Journal:  J Cardiovasc Transl Res       Date:  2011-08-30       Impact factor: 4.132

5.  Intrapericardial delivery of L-arginine reduces the increased severity of ventricular arrhythmias during sympathetic stimulation in dogs with acute coronary occlusion: nitric oxide modulates sympathetic effects on ventricular electrophysiological properties.

Authors:  L Fei; A D Baron; D P Henry; D P Zipes
Journal:  Circulation       Date:  1997-12-02       Impact factor: 29.690

6.  Intrapericardial therapeutics: a pharmacodynamic and pharmacokinetic comparison between pericardial and intravenous procainamide delivery.

Authors:  Michael R Ujhelyi; Kelly Z Hadsall; David E Euler; Rahul Mehra
Journal:  J Cardiovasc Electrophysiol       Date:  2002-06

7.  Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation.

Authors:  G M Ayers; T H Rho; J Ben-David; H R Besch; D P Zipes
Journal:  J Cardiovasc Electrophysiol       Date:  1996-08

8.  Potent antifibrillatory effects of intrapericardial nitroglycerin in the ischemic porcine heart.

Authors:  Kapil Kumar; Khanh Nguyen; Sergio Waxman; Bruce D Nearing; Gregory A Wellenius; Susan X Zhao; Richard L Verrier
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

9.  Intrapericardial ibutilide administration fails to terminate pacing-induced sustained atrial fibrillation in dogs.

Authors:  András Vereckei; J Cristopher Gorski; Michael Ujhelyi; Rahul Mehra; Douglas P Zipes
Journal:  Cardiovasc Drugs Ther       Date:  2004-07       Impact factor: 3.727

10.  Pericardial delivery of omega-3 fatty acid: a novel approach to reducing myocardial infarct sizes and arrhythmias.

Authors:  Yong-Fu Xiao; Daniel C Sigg; Michael R Ujhelyi; Joshua J Wilhelm; Eric S Richardson; Paul A Iaizzo
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-03-07       Impact factor: 4.733

View more
  1 in total

1.  Effects of ATP administration on isolated swine hearts: Implications for ex vivo perfusion and cardiac transplantation.

Authors:  Maria S Seewald; Erik N Gaasedelen; Tinen L Iles; Lars M Mattison; Alexander R Mattson; Megan M Schmidt; Ruediger C Braun-Dullaeus; Paul A Iaizzo
Journal:  Exp Biol Med (Maywood)       Date:  2019-05-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.